You are here
Frank D’Amelio is the executive vice president, business operations and chief financial officer of Pfizer, responsible for finance, business development and business operations, including IT, procurement and real estate. Frank led the acquisition and integration of Medivation, Inc., Anacor Pharmaceuticals Inc., Hospira Inc., King Pharmaceuticals Inc. and Wyeth, as well as the split-off of Pfizer’s animal health business, Zoetis, and the sale of its nutrition business to Nestle and its Capsugel business to KKR.
Before joining the company in September 2007, he was senior executive vice president of integration and chief administrative officer of Alcatel-Lucent, responsible for the integration of the Alcatel-Lucent merger as well as procurement, real estate, IT and supply chain.
Prior to the merger of Alcatel and Lucent Technologies in 2006, Frank was the chief operating officer of Lucent Technologies. In 2001, he was appointed executive vice president and chief financial officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry’s history and returned the company to profitability.
When Lucent was spun off from AT&T in 1996, Frank helped create the new company financially as the chief financial officer of Lucent’s Network Systems Business and was a critical member of the team that met with investors around the world during Lucent’s initial public offering. In 1999, he was appointed the Group President of Lucent’s Switching Solutions Business Unit, where he led Lucent’s multibillion-dollar, global Switching, Access and Application Software businesses.
Born and raised in New Jersey, Frank earned his M.B.A. in Finance from St. John’s University and his B.A. in Accounting from St. Peter’s College. He started his career in 1979 at Bell Labs, holding a variety of financial, accounting and general management positions, and moved within AT&T, holding a series of positions with increasing responsibility.
In 2005, 2006, 2011, 2012, 2013, 2014 and 2016, Frank was ranked among America’s top CFOs by Institutional Investor magazine. In 2002, he was recognized by Treasury & Risk Magazine as one of America’s Top CFOs.
He currently serves on the Board of Directors of Zoetis, Inc. and Humana, Inc. and is chair of the Humana Audit Committee; and the Independent College Fund of New Jersey.